Is HOWL or RVPH more profitable?

Werewolf Therapeutics' return on equity of -208.23% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer HOWL or RVPH?

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat Werewolf Therapeutics' score of 0.29 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AKTX or RVPH?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is AKTX or RVPH more profitable?

Akari Therapeutics' return on equity of -123.29% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer AKTX or RVPH?

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for Akari Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat Akari Therapeutics' score of 0.47 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, MTVA or RVPH?

MetaVia is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is MTVA or RVPH more profitable?

MetaVia's return on equity of -172.92% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media refer more to MTVA or RVPH?

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than MetaVia. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for MetaVia. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat MetaVia's score of 0.07 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AEON or RVPH?

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 10,650.95%. Given Reviva Pharmaceuticals' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than AEON Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, AEON or RVPH?

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$5.00 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is AEON or RVPH more profitable?

AEON Biopharma's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media refer more to AEON or RVPH?

In the previous week, AEON Biopharma had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for AEON Biopharma and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat AEON Biopharma's score of 0.81 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVPH or HCWB?

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for HCW Biologics. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat HCW Biologics' score of 1.06 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Reviva Pharmaceuticals (RVPH) Competitors

$0.62 +0.03 (+4.52%)

As of 03:12 PM Eastern

Compare

RVPH vs. HOWL, AKTX, MTVA, AEON, and HCWB

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include Werewolf Therapeutics (HOWL), Akari Therapeutics (AKTX), MetaVia (MTVA), AEON Biopharma (AEON), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry.

How does Reviva Pharmaceuticals compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 11 mentions for Werewolf Therapeutics and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat Werewolf Therapeutics' score of 0.29 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 762.07%. Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 10,650.95%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Reviva Pharmaceuticals has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	11.25	-$60.82M	-$1.24	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Werewolf Therapeutics' return on equity of -208.23% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Werewolf Therapeutics and Reviva Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Akari Therapeutics currently has a consensus price target of $89.00, suggesting a potential upside of 468.29%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 10,650.95%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Akari Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 30.7% of Akari Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for Akari Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat Akari Therapeutics' score of 0.47 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akari Therapeutics' return on equity of -123.29% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Summary

Reviva Pharmaceuticals beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than MetaVia. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for MetaVia. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat MetaVia's score of 0.07 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 711.69%. Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 10,650.95%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

MetaVia's return on equity of -172.92% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

MetaVia has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

MetaVia is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats MetaVia on 9 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 10,650.95%. Given Reviva Pharmaceuticals' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, AEON Biopharma had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for AEON Biopharma and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat AEON Biopharma's score of 0.81 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AEON Biopharma's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

AEON Biopharma and Reviva Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to HCW Biologics?

Reviva Pharmaceuticals (NASDAQ:RVPH) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Reviva Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Reviva Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Reviva Pharmaceuticals' return on equity of -391.58% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
HCW Biologics	-34.73%	-486.87%	-29.19%

Reviva Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 10,650.95%. HCW Biologics has a consensus price target of $5.00, indicating a potential upside of 207.50%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Reviva Pharmaceuticals is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HCW Biologics has higher revenue and earnings than Reviva Pharmaceuticals. HCW Biologics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
HCW Biologics	$50K	218.86	-$7.96M	-$9.46	N/A

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for HCW Biologics. Reviva Pharmaceuticals' average media sentiment score of 1.32 beat HCW Biologics' score of 1.06 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Reviva Pharmaceuticals beats HCW Biologics on 10 of the 15 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.13M	$2.96B	$6.43B	$12.49B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.15	18.10	23.86	24.42
Price / Sales	N/A	298.31	521.12	117.04
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	0.42	3.94	10.04	6.74
Net Income	-$19.86M	$75.85M	$3.56B	$337.03M
7 Day Performance	43.21%	-1.40%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-96.19%	22.88%	28.80%	34.36%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	3.0466 of 5 stars	$0.62 +4.5%	$66.67 +10,651.0%	-96.4%	$8.13M	N/A	N/A	5	Positive News
HOWL Werewolf Therapeutics	3.6412 of 5 stars	$0.44 flat	$3.75 +745.4%	-68.9%	$21.56M	$1.88M	N/A	40	News Coverage Gap Up
AKTX Akari Therapeutics	2.3727 of 5 stars	$18.27 flat	$89.00 +387.1%	-73.1%	$20.91M	N/A	N/A	9	High Trading Volume
MTVA MetaVia	2.3535 of 5 stars	$3.85 flat	$20.00 +419.5%	-63.7%	$19.88M	N/A	N/A	8	High Trading Volume
AEON AEON Biopharma	1.5763 of 5 stars	$0.78 flat	N/A	+24.1%	$19.67M	N/A	4.32	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. HOWL, AKTX, MTVA, AEON, and HCWB

How does Reviva Pharmaceuticals compare to Werewolf Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Akari Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to MetaVia?

Summary

How does Reviva Pharmaceuticals compare to AEON Biopharma?

Summary

How does Reviva Pharmaceuticals compare to HCW Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. HOWL, AKTX, MTVA, AEON, and HCWB

How does Reviva Pharmaceuticals compare to Werewolf Therapeutics?

Which has more volatility and risk, HOWL or RVPH?

Does the media prefer HOWL or RVPH?

Do analysts prefer HOWL or RVPH?

Which has higher earnings and valuation, HOWL or RVPH?

Is HOWL or RVPH more profitable?

Do insiders & institutionals believe in HOWL or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Akari Therapeutics?

Do analysts prefer AKTX or RVPH?

Which has more volatility and risk, AKTX or RVPH?

Do institutionals and insiders hold more shares of AKTX or RVPH?

Does the media prefer AKTX or RVPH?

Is AKTX or RVPH more profitable?

Which has preferable valuation & earnings, AKTX or RVPH?

Summary

How does Reviva Pharmaceuticals compare to MetaVia?

Does the media refer more to MTVA or RVPH?

Do analysts prefer MTVA or RVPH?

Is MTVA or RVPH more profitable?

Which has more risk and volatility, MTVA or RVPH?

Which has preferable earnings & valuation, MTVA or RVPH?

Do insiders & institutionals hold more shares of MTVA or RVPH?

Summary

How does Reviva Pharmaceuticals compare to AEON Biopharma?

Which has preferable earnings and valuation, AEON or RVPH?

Which has more risk and volatility, AEON or RVPH?

Do analysts rate AEON or RVPH?

Does the media refer more to AEON or RVPH?

Do insiders & institutionals have more ownership in AEON or RVPH?

Is AEON or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to HCW Biologics?

Which has more risk & volatility, RVPH or HCWB?

Do insiders and institutionals believe in RVPH or HCWB?

Is RVPH or HCWB more profitable?

Do analysts rate RVPH or HCWB?

Which has preferable valuation and earnings, RVPH or HCWB?

Does the media favor RVPH or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools